Paint Therapeutics is a leading biotechnology company dedicated to enhancing the quality of life through breakthrough discoveries in the field of biopharmaceuticals. With a focus on innovative research and development, we strive to address unmet medical needs and revolutionize the treatment of various diseases.
Our team of experts is passionate about making a difference in the lives of patients around the world. We believe that by pushing the boundaries of science and technology, we can unlock new therapeutic possibilities that have the potential to transform healthcare.
Mr. Bill Reddick, CEO
With a rich background spanning 30 years, Bill has steered successful ventures in financial and executive management within the pharmaceutical sector. Previously serving as Founder and CFO of Celtaxsys, he orchestrated fundraising efforts totaling $80 million and forged strategic alliances with renowned institutions. Bill’s expertise encompasses supply chain optimization, strategic consulting, and financial analysis, positioning him to catalyze impactful innovation in healthcare. Connect with Bill to explore collaborative opportunities and propel advancements in the pharmaceutical landscape.
Eric Springman, PhD, COO
During his 25-year industry career, Dr Springman has brought many new investigational medicines from discovery to clinic in disease conditions ranging from inflammation and fibrosis to osteoporosis and cancer. He completed his postdoctoral training in Clinical Pharmacology and Immunology at Vanderbilt University School of Medicine, where he was an American Lung Association Research Fellow. He holds a PhD in Molecular Biophysics from Florida State University, where his graduate work was presented at the 1998 Nobel Mini-Forum. Dr Springman is a past member of the Pennsylvania Drug, Device and Cosmetics Board and the GABIO Board of Directors.
Frank Guarnieri, PhD, CSO
With over two decades of experience, Frank has been at the forefront of transformative discoveries and technological advancements. Currently serving as the Chief Scientific Officer at Paint Therapeutics, Frank leads efforts to create innovative treatments, leveraging his expertise in pulmonary surfactant linked technology. Prior to this role, Frank pioneered groundbreaking technologies as the Chief Technology Officer at CO2Change, where he invented methods for transforming CO2 into carbon using UV light, with applications ranging from renewable energy to carbon sequestration. Frank’s academic journey began with a Doctorate in Chemistry from New York University, followed by extensive postdoctoral research and patent inventions. Throughout his career, Frank has held key positions at renowned institutions such as the Center for Drug Discovery at Northeastern University and Solmap Pharmaceuticals, Inc., where he played pivotal roles in drug discovery and development. With a track record of securing funding, leading multidisciplinary teams, and driving innovation, Frank is poised to continue shaping the future of pharmaceutical research.